


# Implementing Best Practice: Collaborating for Better Care Partnership

AHSN NENC has an established partnership with the North East Quality Observatory (NEQOS). On behalf of the AHSN, NEQOS is responsible for creating and supporting a collaborative concerned with improving clinical quality, reducing clinical variation and improving patient outcomes by enabling more rapid and effective implementation of best practice guidance.



The Collaborating for Better Care Partnership (CfBCP) - was launched in Spring 2014 to:


- Develop a regional understanding of the challenges to, and opportunities for, more effective implementation of NICE and other best practice guidance;
- Build skills and knowledge in effective implementation of NICE and other best practice guidance;
- Spread and facilitate best practice in effective implementation of NICE and other best practice guidance;
- Champion leadership for effective implementation of NICE and other best practice guidance.

The CfBCP provides cross cutting support to all of the AHSN work programmes and hosts regular workshops and masterclasses to promote and share expertise in effective implementation.

Its action plans and strategy were developed to reflect stakeholder needs and concerns, following a telephone survey of approaches to implementation in CCGs and Trusts in the region.



Further details of the survey and full details of the workshops and masterclasses are available on the AHSN website



## Technology Appraisals (TA)

The CfBCP has worked with Regional partners to coordinate an assessment of the uptake of a range of NICE TAs:

- Natalizumab for multiple sclerosis – TA 127, August 2007
- Fingolimod for multiple sclerosis – TA 254, April 2012
- Pirfenidone for idiopathic pulmonary fibrosis – TA 282 April 2013
- Azacitidine: TA218, March 2011, Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
- Mifamurtide: TA235, October 2011, Mifamurtide for the treatment of osteosarcoma
- Erlotinib: TA258, June 2012, Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
- Erlotinib: TA162, November 2008, Erlotinib for the treatment of non-small-cell lung cancer (i.e. 2<sup>nd</sup> line)

The four key components to ensuring that best practice guidance is implemented effectively - ReACH

